Austin-based Viagen Inc. and Monash Institute of Melbourne, Australia decide to form a joint stem cell bank for horses. The performance-horse industry could be among the first to benefit from the harnessing of embryonic stem cells to repair tendon, ligament, cartilage and bone damage, the partners say, though they expect the work to have far wider applications.
At a news release from the joint cell bank, it has been informed that therapeutic cells will be recognized by a horse’s immune system as its own so there will be no risk of tissue rejection.
Current stem-cell therapies involve aspirating adipose (fat) cells or bone-marrow cells from the injured horse, which are sent to a laboratory and grown into the required tissue cells over a period of up to three weeks.
Source: dvm 360